Decision to Cancel 160,622 Treasury Shares… Aimed at Enhancing Shareholder Value, 1.12% Reduction in Outstanding Shares


  • Scale of cancellation: 160,622 common shares (approx. 1.12% of total outstanding) to be cancelled on June 15, 2026. Post-cancellation total shares decrease from 14,378,896 to 14,218,274.
  • Funding: Cancellation uses previously acquired treasury shares within distributable profits; no capital reduction. Cancellation amount is 499.7 million KRW (based on average acquisition cost per share).
  • Purpose & Background: Board resolution to enhance shareholder value. Utilizes existing treasury shares without additional funding.
  • Impact on shareholders: Reduction in outstanding shares increases EPS and book value per share. Existing shareholders' ownership slightly rises, a positive effect.
  • [AI Comprehensive Analysis]The treasury share cancellation is a clear shareholder return policy and a positive signal. However, the cancellation ratio of 1.12% is modest, limiting short-term price impact. It demonstrates a long-term commitment to value enhancement.

KOSDAQ Filing Information


  • Filing: Decision on Retirement of Shares
  • Company: Aligned Genetics (238120)
  • Submission: Aligned Genetics, Inc.
  • Receipt: 05-29-2026
  • Under KRX KOSDAQ Market Division